Slate Medicines’ Merger with Fulcrum and $245M Private Placement Accelerate Dual-Target Migraine Therapy

Slate Medicines launched earlier this year backed by a substantial financing round, initially positioning its migraine drug candidate as a best-in-class option. Following its announcement to merge with Nasdaq-listed Fulcrum Therapeutics, the company is now revealing further details about its approach to addressing the $5 billion global migraine market.

Current migraine antibody treatments primarily target calcitonin gene-related peptide (CGRP). However, research indicates that pituitary adenylate cyclase-activating polypeptide (PACAP) also plays a significant role in migraine pain. Slate’s SLTE-1009, licensed from China-based DartsBio Pharmaceuticals, is a monoclonal antibody designed to simultaneously block PACAP and vasoactive intestinal peptide (VIP), offering a dual-targeting strategy that could differentiate it from existing and emerging therapies.

Several major pharmaceutical companies have advanced PACAP inhibitors through clinical development. Amgen and Eli Lilly encountered limitations, and Lundbeck—through its 2019 acquisition of Alder BioPharmaceuticals—continues development of bocunebart, an intravenously infused PACAP-blocking antibody. At the recent American Headache Society Congress, Lundbeck presented Phase 2b data demonstrating bocunebart achieved a statistically significant reduction in headache days compared to placebo.

The PACAP drug development landscape is attracting new entrants. In June, Seattle-based Vedana Therapeutics emerged from stealth with $46 million in Series A funding to advance a pipeline of long-acting antibodies. The company’s lead program targets PACAP, while a second program explores a bispecific antibody addressing both PACAP and CGRP. Notably, Vedana, like Slate and Lundbeck, includes former Alder employees, including Chief Medical Officer Roger Cady.

During a Monday morning conference call, Slate Chief Executive Gregory Oakes stated that SLTE-1009 may offer improved efficacy over PACAP-only targeting therapeutics. A key differentiator is dosing convenience: while Lundbeck’s bocunebart requires monthly intravenous infusions, SLTE-1009 is being developed for subcutaneous administration, with half-life engineering that could enable dosing as infrequently as every quarter.

Slate’s claims are grounded in preclinical data outlined in an investor presentation. The company is now advancing toward clinical validation, beginning with a Phase 1 trial in healthy volunteers expected in Australia. Preliminary results are anticipated in mid-2027, followed by a Phase 2 dose-range finding study in migraine patients slated for the second half of next year.

The Slate pipeline extends beyond SLTE-1009. SLTE-2100 is a preclinical bispecific antibody engineered with one arm targeting PACAP/VIP and the other targeting CGRP, with clinical initiation expected in the second half of 2027. Additionally, the company retains a confidential second migraine program.

Slate’s reverse merger with Fulcrum arrives approximately six months after the biotech’s launch, which was supported by a $130 million Series A round led by RA Capital, Forbion, and Foresite Capital. Several of those firms, along with Frazier Life Sciences, are participating in the concurrent $245 million private placement. Additional participants include Deep Track Capital, OrbiMed, RTW Investments, and Mingxin Capital. Fulcrum, whose former lead program was pociredir for sickle cell disease, discontinued development in June due to FDA concerns regarding cancer risks associated with its drug class, and is now exploring strategic alternatives.

The Slate-Fulcrum business combination requires shareholder approval from both companies and is expected to close in the fourth quarter of this year. Upon completion, pre-merger Slate stockholders will hold approximately 55.9% of the combined entity, private placement investors will own about 39.1%, and pre-merger Fulcrum shareholders will retain roughly 5%. The merged company will trade on the Nasdaq under the ticker “SLTE.”

Source link